V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220019921 | 220009401 | 1.72 | 78.1 | null | 2016-11-11 | 2016-12-09 | ALL UKALL2011 TRIAL | 02 | N | 220035535 | GEMCITABINE |
| 220019925 | 220014991 | 1.69 | 60 | Curative (C) | 2015-01-08 | 2015-01-09 | Cytarabine + Idarubicin | N | null | 220035549 | MA |
| 220019926 | 220009413 | null | null | Palliative (P) | 2017-09-19 | 2017-09-19 | GDP | N | null | 220035566 | METHOTREXATE HIGH DOSE |
| 220019927 | 220009420 | 1.73 | 86.5 | Curative (C) | 2015-02-22 | 2015-02-25 | CAMELLIA Trial | N | N | 220035603 | AFATINIB |
| 220019928 | 220009423 | 1.74 | 63.6 | Curative (C) | 2014-08-22 | 2014-08-29 | DABRAFENIB | N | N | 220035632 | DOXORUBICIN |
| 220019929 | 220009427 | 1.6 | 62.3 | Curative (C) | 2016-07-08 | 2016-07-16 | Carboplatin AUC 6 - 10 | N | N | 220035638 | FCR |
| 220019930 | 220009432 | 1.67 | 55.8 | null | 2014-07-28 | 2015-08-06 | MA (Cytarabine 3g/m2) | N | N | 220035672 | PEMBROLIZUMAB |
| 220019931 | 220009438 | 1.67 | 51.3 | Curative (C) | 2018-04-13 | 2018-04-24 | PEMBROLIZUMAB | 02 | N | 220035738 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220019932 | 220009439 | null | 95 | Curative (C) | 2017-05-09 | 2017-10-04 | MidAC | null | N | 220035742 | LIPOSOMAL CYTARABINE |
| 220019934 | 220015008 | 1.6 | null | Curative (C) | 2017-09-11 | 2018-04-14 | Arsenic Triox + Tretinoin Ind W1-4 | 3 | N | 220035765 | WT1 TRIAL |
| 220019936 | 220009451 | 1.56 | 120 | Curative (C) | 2016-11-13 | 2016-11-20 | Fluorouracil + Folinic Acid Weekly | 2 | N | 220035793 | MITOXANTRONE + TRETINOIN |
| 220019937 | 220015014 | 1.3 | null | Curative (C) | 2015-01-19 | 2015-01-19 | FLUDARABINE | N | N | 220035797 | IMATINIB + HYDROXYCARBAMIDE |
| 220019938 | 220015019 | 1.71 | 80.4 | Curative (C) | 2015-05-28 | 2015-06-01 | DABRAFENIB + TRAMETINIB | N | N | 220035882 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 220019939 | 220009471 | 1.69 | 62.2 | Curative (C) | 2014-10-30 | 2014-12-20 | Liposomal Doxorubicin (Caelyx) | Y | N | 220035925 | UKALL 2011 |
| 220019940 | 220018197 | null | null | Curative (C) | 2013-12-14 | 2013-12-14 | MELPHALAN | null | null | 220035943 | ALEMTUZUMAB + FLUDARABINE |
| 220019941 | 220009475 | 1.69 | 80 | Curative (C) | 2017-04-22 | 2017-05-10 | PEMBROLIZUMAB | 01 | N | 220035947 | CETUXIMAB |
| 220019942 | 220009481 | 1.83 | 108.5 | Curative (C) | 2017-05-11 | 2017-05-18 | Fludarabine IV | 1 | N | 220035962 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220019943 | 220015033 | 1.75 | 102.7 | Palliative (P) | 2015-12-26 | 2016-01-07 | CETUXIMAB + RT | N | N | 220036003 | IPILIMUMAB |
| 220019944 | 220009489 | 1.8 | 111 | Curative (C) | 2014-02-25 | 2014-05-20 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | 02 | N | 220036013 | CYTARABINE + MITOXANTRONE |
| 220019945 | 220009492 | 0 | 72.1 | Not known (9) | 2014-12-21 | 2015-03-12 | ATG + BUSULFAN + CYCLOPHOSPHAMIDE | N | N | 220036034 | ROMAZA TRIAL |
| 220019946 | 220015037 | null | 88.3 | null | 2014-05-26 | 2014-06-09 | DA-EPOCH-R | 02 | N | 220036041 | LENALIDOMIDE |
| 220019947 | 220009495 | 1.83 | 69 | Curative (C) | 2015-08-25 | 2016-10-30 | CISPLATIN + ETOPOSIDE | N | N | 220036053 | BUSULFAN + CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019948 | 220009497 | 1.64 | 80 | Disease modification (D) | 2016-12-11 | 2016-12-16 | FEC 100 | N | N | 220036057 | TRASTUZUMAB |
| 220019949 | 220009500 | 1.76 | 83 | Palliative (P) | 2015-03-26 | 2015-08-24 | DABRAFENIB | 2 | N | 220036062 | PEMETREXED |
| 220019950 | 220009510 | null | null | Curative (C) | 2015-10-14 | 2015-10-14 | BUSULFAN + CYCLO | N | Y | 220036121 | FLUDARABINE |
| 220019952 | 220009526 | 1.65 | null | Curative (C) | 2015-10-13 | 2015-11-20 | Spanish Maintenance (Months 4-24) | null | null | 220036202 | PERTUZUMAB |
| 220019953 | 220009530 | 1.67 | 54.2 | Curative (C) | 2014-09-20 | 2014-09-21 | MidAC | N | N | 220036215 | ARSENIC TRIOXIDE + ATRA |
| 220019954 | 220009533 | 1.71 | 71.8 | Curative (C) | 2016-07-06 | 2016-07-12 | INTERFERON | 02 | N | 220036225 | CAPECITABINE + OXALIPLATIN |
| 220019955 | 220019992 | 1.78 | null | null | 2017-12-02 | 2017-12-02 | MELPHALAN | N | N | 220036228 | EOX |
| 220019957 | 220009539 | 1.83 | 83.2 | Curative (C) | 2017-03-17 | 2017-06-16 | Cetuximab 14 day | N | N | 220036240 | UKALL 2011 |
| 220019958 | 220019993 | 1.7 | 84.8 | Curative (C) | 2018-11-30 | 2019-01-03 | Arsenic trioxide | N | N | 220036248 | CAMELLIA TRIAL |
| 220019959 | 220021928 | 1.75 | null | Disease modification (D) | 2017-09-15 | 2017-09-26 | FIGARO TRIAL | N | N | 220036280 | CYTARABINE + ETOPOSIDE |
| 220019960 | 220009547 | null | null | Curative (C) | null | 2015-07-11 | Cytarabine+Methotrexate Intrathecal | N | null | 220036297 | CYTARABINE IT + METHOTREXATE |
| 220019961 | 220009550 | 1.65 | 65.7 | Disease modification (D) | 2016-12-01 | 2017-05-17 | BUSULFAN + FLUDARABINE + METHOTREXATE | 02 | N | 220036312 | IPO |
| 220019962 | 220009558 | 1.78 | 94.2 | null | 2016-12-15 | 2017-05-21 | Arsenic Triox + Tretinoin Ind W1-4 | 01 | N | 220036334 | LENALIDOMIDE |
| 220019963 | 220009559 | null | 74 | Palliative (P) | 2016-09-12 | 2016-10-20 | ALEMTUZUMAB + FLUDARABINE | 02 | N | 220036338 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN |
| 220019964 | 220009566 | null | null | Curative (C) | 2014-05-18 | 2014-05-18 | DA-EPOCH-R | N | N | 220036395 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220019965 | 220009571 | 1.57 | 0 | Disease modification (D) | 2017-05-09 | 2017-06-19 | CYTARABINE + FLUDARABINE | 2 | N | 220036412 | IRINOTECAN |
| 220019966 | 220009572 | 1.71 | 105 | Palliative (P) | 2017-02-25 | 2017-03-01 | DABRAFENIB | N | N | 220036413 | PEMBROLIZUMAB |
| 220019967 | 220009577 | null | null | Curative (C) | 2018-03-05 | 2018-03-05 | LENALIDOMIDE | null | null | 220036432 | ETOPOSIDE + IDARUBICIN |
| 220019968 | 220009587 | 1.81 | 97 | Curative (C) | 2017-07-16 | 2017-09-20 | CYTARABINE + MITOXANTRONE | 01 | N | 220036453 | FIGARO TRIAL |
| 220019969 | 220018225 | 1.8 | 79.9 | Palliative (P) | 2016-12-21 | 2017-03-14 | MERCAPTOPURINE + METHOTREXATE | N | N | 220036524 | UKALL 2011 |
| 220019971 | 220009607 | 1.62 | 96.8 | Curative (C) | 2018-05-15 | 2018-05-20 | INTERFERON | 02 | N | 220036563 | INTERFERON |
| 220019972 | 220009610 | 1.84 | 41.2 | Disease modification (D) | 2014-06-19 | 2014-07-02 | MidAC | N | N | 220036575 | IBRUTINIB |
| 220019973 | 220009619 | null | 86 | Palliative (P) | 2014-07-10 | 2014-07-16 | TIP | 99 | null | 220036606 | CYTARABINE IT + METHOTREXATE |
| 220019974 | 220009625 | 1.86 | null | Curative (C) | 2015-03-07 | 2015-12-31 | MACE | N | N | 220036614 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220019975 | 220018230 | null | 64.7 | Disease modification (D) | 2012-12-29 | 2012-12-29 | VIDE | N | N | 220036619 | VINORELBINE |
| 220019976 | 220009630 | 1.68 | 73.8 | Curative (C) | 2017-10-03 | 2017-10-03 | IPM | 02 | N | 220036629 | BUSULPHAN + CYCLO |
| 220019977 | 220009636 | 1.65 | 125 | Disease modification (D) | 2017-05-22 | 2017-05-26 | Busulfan + Cyclophos Conditioning | N | N | 220036633 | MITOXANTRONE + TRETINOIN |
| 220019978 | 220009640 | 1.72 | 72.5 | Disease modification (D) | 2014-11-04 | 2014-11-11 | EOX | 02 | N | 220036641 | CETUXIMAB + IRINOTECAN + MDG |